The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome
Abstract
Background Early, intensive statin treatment is the standard of care after acute coronary syndrome (ACS). However, the benefit of this approach to prevent major adverse cardiovascular events has been demonstrated in only one randomised, placebo controlled trial. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial demonstrated that atorvastatin 80 mg daily, compared with placebo, reduced time to first occurrence of death, non-fatal myocardial infarction, resuscitated cardiac arrest, or hospitalisation for unstable angina (stroke not included) during the 16 week period following ACS. However, there were no significant effects on individual components of the composite endpoint except unstable angina. This led some to question whether early, intensive statin treatment reduces 'hard' events after ACS. Aim The burden of coronary heart disease after ACS, and therefore the efficacy of its treatment, depends not only on the occurrence of one ischaemic event, but rather on cumulative events experienced by patients. Accordingly, we conducted a post-hoc analysis of the MIRACL trial to examine the effect of atorvastatin on first as well as recurrent (i.e. total) hard cardiovascular events after ACS (death, myocardial infarction, stroke, and resuscitated cardiac arrest). Methods and Results In the 3086 patients who comprised the MIRACL trial, atorvastatin 80 mg did not reduce time to first hard event compared with placebo (hazard ratio 0.89, 95% confidence interval 0.72-1.10, P = 0.27). However, atorvastatin significantly reduced total hard events (hazard ratio 0.80, 95% confidence interval 0.66-0.97, P = 0.03). To prevent one hard event during the 16 weeks following ACS, only 11 patient-years of treatment with atorvastatin were required. Conclusion Early, intensive treatment with atorvastatin is an efficient intervention to reduce hard cardiovascular events after ACS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The same benefits were also recently demonstrated for diabetic patients after ACS in the ODYSSEY trial [420].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [420]
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citationAnker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 115 · cited 1×
“There is increasing recognition that analysis of recurrent events is an approach that may better estimate the total impact of cardiovascular disease on the patient, and provide a means to enhance the efficiency of clinical trials.(4) Accordingly, we conducted a post-hoc analysis of the effect of atorvastatin on first…”
BackgroundGauging the Impact of Statins Using Number Needed to Treat
Kumana, C. R., Cheung, B. M., & Lauder, I. J. (1999) · JAMA · doi:10.1001/jama.282.20.1899 · Cited by 76 · cited 1×
“Scandinavian Simvastatin Survival Study of patients with chronic coronary heart disease.(5) This analysis demonstrates that when total events are considered, early intensive treatment with atorvastatin is an efficient intervention to reduce hard cardiovascular outcomes following ACS.”
BackgroundArnold, S. V., Kosiborod, M., Tang, F., Zhao, Z., Maddox, T. M., McCollam, P. L., Birt, J. A., & Spertus, J. A. (2014) · Circulation · doi:10.1161/circulationaha.113.003589 · Cited by 72
Briel, M., Vale, N., Schwartz, G. G., de Lemos, J. A., Colivicchi, F., den Hartog, F. R., Ošťádal, P., Macin, S. M., Liem, A. H., Mills, E., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.01.033 · Cited by 34
Self-citation
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Edelberg, J. M., Goodman, S. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.039 · Cited by 173
Self-citationMehta, S. R., Paré, G., Lonn, E., Jolly, S. S., Natarajan, M. K., Pinilla‐Echeverri, N., Schwalm, J.-D., Sheth, T., Sibbald, M., Tsang, M., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-22-00735 · Cited by 84
Leósdóttir, M., Schubert, J. R., Brandts, J., Gustafsson, S., Cars, T., Sundström, J., Jernberg, T., Ray, K. K., & Hagström, E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.007 · Cited by 72
Metadata
- Authors
- Schwartz, G. G., Fayyad, R., Szarek, M., DeMicco, D., & Olsson, A. G.
- Affiliations
- VA Medical Center and University of Colorado, USA
- Pfizer (United States) (US)
- SUNY Downstate Health Sciences University (US)
- Linköping University (SE)
- Corresponding author
- Schwartz, Gregory G
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-15
- Volume
- 24
- Issue
- 12
- Pages
- 1294-1296
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2615974387
- Cited by
- 44
- References
- 7
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 15 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 2
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, atorvastatin, statin therapy, recurrent cardiovascular events, post hoc analysis, myocardial infarction, stroke, resuscitated cardiac arrest
- MeSH terms
- Cause of Death, Dose-Response Relationship, Drug, Humans, Morbidity, Global Health, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome. https://app.cochat.ai/papers/10.1177/2047487317708677
- The paper
- Schwartz, G. G., Fayyad, R., Szarek, M., DeMicco, D., & Olsson, A. G. (2017). Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487317708677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.